Abstract: The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The disclosure includes therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits, as well as nucleic acid molecules encoding the albumin fusion proteins, vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins using these nucleic acids, vectors, and/or host cells. The disclosure further relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion.

Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits.

Abstract: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits.

Abstract: The present invention relates to a method for the production of antithrombin III with antiangiogenic activity from coagulation-active (native) antithrombin III and the utilisation of coagulation-active antithrombin III for the prophylaxis and therapy of diseases.

Abstract: We have now discovered that partially deglycosylated vitamin D binding protein (DBP-maf) is anti-tumorigenic not wholly via an immune mechanism but in part via an antiangiogenic mechanism. Accordingly, the present invention relates to use of DBP-maf in the treatment of diseases associated with increased or abnormal angiogenesis and/or endothelial cell differentiation. Preferably, the DBP-maf is administered to the patient by sustained release or in pulses. Pulse therapy is not a form of discontinuous administration of the same account of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.